Related Experiment Video
Updated: Jul 13, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
Linking SIRT2 to Parkinson's disease.
Adam L Garske1, Brian C Smith, John M Denu
1Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
ACS Chemical Biology
|August 22, 2007
Summary
Selective inhibitors of silent information regulator 2 (SIRT2) show promise in protecting against Parkinson's disease. These compounds reduce alpha-synuclein toxicity and dopaminergic cell death in cellular and animal models.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Parkinson's disease is characterized by alpha-synuclein toxicity and dopaminergic neuron loss.
- Silent information regulator 2 (SIRT2) is a NAD(+)-dependent protein deacetylase implicated in cellular processes.
- Targeting SIRT2 presents a potential therapeutic strategy for neurodegenerative diseases.
Purpose of the Study:
- To identify and evaluate selective inhibitors of SIRT2.
- To assess the neuroprotective effects of SIRT2 inhibitors against alpha-synuclein toxicity.
- To investigate the potential of SIRT2 inhibition as a treatment for Parkinson's disease models.
Main Methods:
- Identification of selective small-molecule inhibitors of human SIRT2.
- In vitro testing of inhibitors in cellular models of Parkinson's disease.
- In vivo evaluation using a Drosophila melanogaster model of Parkinson's disease.
Main Results:
- Selective SIRT2 inhibitors were identified.
- These compounds demonstrated protection against alpha-synuclein-mediated toxicity.
- Inhibitors ameliorated dopaminergic cell death in both cellular and Drosophila models.
Conclusions:
- SIRT2 inhibitors offer a potential therapeutic avenue for Parkinson's disease.
- The protective mechanism may involve promoting enlarged inclusion bodies for cell survival.
- Further research is warranted to elucidate the precise molecular mechanisms.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...